|
A federal study funded by the National Institutes of Health found that individuals taking the diabetes and obesity drugs Ozempic and Wegovy had a lower risk of suicidal thoughts compared to those taking other medications for the same conditions. The study, based on the analysis of electronic medical records from over 1.8 million patients, aims to address concerns raised by anecdotal reports linking the drug semaglutide to thoughts of self-harm, urging further evaluation and longer follow-up periods for patients.
|
Eli Lilly has introduced a new website, LillyDirect, allowing patients to obtain prescriptions for weight loss drugs through telehealth providers, streamlining access to medications such as Zepbound. While the move aims to enhance accessibility, experts express concerns about potential conflicts of interest and the need for careful oversight of the platform to avoid fragmentation of care and ensure appropriate prescriptions.
|
The FDA has approved Florida's plan to import prescription drugs from Canada, marking a significant shift in U.S. drug policies and aiming to enhance access to more affordable medications in the state. This move is part of a broader effort to address high prescription drug prices and encourage competition in the pharmaceutical market.
|
Wearing hearing aids may reduce the risk of early death, according to a study published in The Lancet Healthy Longevity journal. The research, based on the data of over 10,000 people, found a 24% lower risk of mortality among regular hearing aid users, highlighting the potential connection between hearing health and overall well-being. Additionally, another study published in JAMA Otolaryngology - Head and Neck Surgery suggests that using hearing aids may also be associated with a lower risk of dementia in individuals with hearing loss.
|
A variant known as JN.1, which is a descendant of the omicron variant, is now the predominant COVID-19 strain in the United States, accounting for approximately 61.6% of cases, according to data from the Centers for Disease Control and Prevention (CDC). JN.1, identified as a "variant of interest" by the World Health Organization, has seen a significant increase from its estimated 3.3% prevalence in mid-November.
|
|